Dual antithrombotic therapy in PCI: Potential harm in routine adoption. Issue 3 (16th February 2019)

• Record Type: Journal Article
• Authors: Sardar, Partha; Dawn Abbott, J.
• Is Part Of: Catheterization and cardiovascular interventions. Volume 93:Issue 3(2019)
• Page Start: E185
• Page End: E186
• Publication Date: 2019-02-16
• Subjects: Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.27999
• Languages: English
• ISSNs: 1522-1946

Abstract

Key Points: Randomized clinical trials support the use of dual antithrombotic therapy (DAT) in PCI patients but outcomes in clinical practice are unclear. In this observational study of patients at high risk for thromboembolism and bleeding, routine use of a P2Y12 inhibitor alone compared with DAPT with OAC was associated with a significantly higher risk of ischemic events without a lower risk of bleeding. Future randomized trials and observational analyses of large registries are needed to select the ideal patient population for DAT.